Biological Therapy: Treatment of diseases with biological materials or biological response modifiers, such as the use of GENES; CELLS; TISSUES; organs; SERUM; VACCINES; and humoral agents.Biological Products: Complex pharmaceutical substances, preparations, or matter derived from organisms usually obtained by biological methods or assay.Antirheumatic Agents: Drugs that are used to treat RHEUMATOID ARTHRITIS.Arthritis, Rheumatoid: A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.Phenetidine: Used in the manufacture of acetophenetidin.Antibodies, Monoclonal: Antibodies produced by a single clone of cells.Psoriasis: A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.Arthritis, Psoriatic: A type of inflammatory arthritis associated with PSORIASIS, often involving the axial joints and the peripheral terminal interphalangeal joints. It is characterized by the presence of HLA-B27-associated SPONDYLARTHROPATHY, and the absence of rheumatoid factor.Antibodies, Monoclonal, Humanized: Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.Immunologic Factors: Biologically active substances whose activities affect or play a role in the functioning of the immune system.Dermatologic Agents: Drugs used to treat or prevent skin disorders or for the routine care of skin.Spondylarthritis: Inflammation of the joints of the SPINE, the intervertebral articulations.Receptors, Tumor Necrosis Factor: Cell surface receptors that bind TUMOR NECROSIS FACTORS and trigger changes which influence the behavior of cells.Rheumatic Diseases: Disorders of connective tissue, especially the joints and related structures, characterized by inflammation, degeneration, or metabolic derangement.Antibodies, Monoclonal, Murine-Derived: Antibodies obtained from a single clone of cells grown in mice or rats.Tumor Necrosis Factor-alpha: Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS.Off-Label Use: The practice of prescribing or using a drug outside the scope of the drug's official approved label as designated by a regulatory agency concerning the treatment of a particular disease or condition.Schizophrenia, Catatonic: A type of schizophrenia characterized by abnormality of motor behavior which may involve particular forms of stupor, rigidity, excitement or inappropriate posture.Gastrointestinal Agents: Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion.Anti-Inflammatory Agents: Substances that reduce or suppress INFLAMMATION.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Inflammatory Bowel Diseases: Chronic, non-specific inflammation of the GASTROINTESTINAL TRACT. Etiology may be genetic or environmental. This term includes CROHN DISEASE and ULCERATIVE COLITIS.Crohn Disease: A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.Immunoglobulin G: The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.Immunosuppressive Agents: Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.Immunotherapy: Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.Clinical Trials as Topic: Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.Immunoconjugates: Combinations of diagnostic or therapeutic substances linked with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; or ANTIGENS. Often the diagnostic or therapeutic substance is a radionuclide. These conjugates are useful tools for specific targeting of DRUGS and RADIOISOTOPES in the CHEMOTHERAPY and RADIOIMMUNOTHERAPY of certain cancers.Autoimmune Diseases: Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.Arthritis, Juvenile: Arthritis of children, with onset before 16 years of age. The terms juvenile rheumatoid arthritis (JRA) and juvenile idiopathic arthritis (JIA) refer to classification systems for chronic arthritis in children. Only one subtype of juvenile arthritis (polyarticular-onset, rheumatoid factor-positive) clinically resembles adult rheumatoid arthritis and is considered its childhood equivalent.Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.Severity of Illness Index: Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder.Spondylitis, Ankylosing: A chronic inflammatory condition affecting the axial joints, such as the SACROILIAC JOINT and other intervertebral or costovertebral joints. It occurs predominantly in young males and is characterized by pain and stiffness of joints (ANKYLOSIS) with inflammation at tendon insertions.Methotrexate: An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.Interleukin 1 Receptor Antagonist Protein: A ligand that binds to but fails to activate the INTERLEUKIN 1 RECEPTOR. It plays an inhibitory role in the regulation of INFLAMMATION and FEVER. Several isoforms of the protein exist due to multiple ALTERNATIVE SPLICING of its mRNA.Precursor Cell Lymphoblastic Leukemia-Lymphoma: A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.Clinical Trials, Phase III as Topic: Works about comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the U.S. and in other countries.Antineoplastic Combined Chemotherapy Protocols: The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.Clinical Trials, Phase II as Topic: Works about studies that are usually controlled to assess the effectiveness and dosage (if appropriate) of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques. These studies are performed on several hundred volunteers, including a limited number of patients with the target disease or disorder, and last about two years. This concept includes phase II studies conducted in both the U.S. and in other countries.Nuclear Reprogramming: The process that reverts CELL NUCLEI of fully differentiated somatic cells to a pluripotent or totipotent state. This process can be achieved to a certain extent by NUCLEAR TRANSFER TECHNIQUES, such as fusing somatic cell nuclei with enucleated pluripotent embryonic stem cells or enucleated totipotent oocytes. GENE EXPRESSION PROFILING of the fused hybrid cells is used to determine the degree of reprogramming. Dramatic results of nuclear reprogramming include the generation of cloned mammals, such as Dolly the sheep in 1997.Breast Neoplasms: Tumors or cancer of the human BREAST.Antineoplastic Agents, Hormonal: Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)Tamoxifen: One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.Oncogenes: Genes whose gain-of-function alterations lead to NEOPLASTIC CELL TRANSFORMATION. They include, for example, genes for activators or stimulators of CELL PROLIFERATION such as growth factors, growth factor receptors, protein kinases, signal transducers, nuclear phosphoproteins, and transcription factors. A prefix of "v-" before oncogene symbols indicates oncogenes captured and transmitted by RETROVIRUSES; the prefix "c-" before the gene symbol of an oncogene indicates it is the cellular homolog (PROTO-ONCOGENES) of a v-oncogene.Breast: In humans, one of the paired regions in the anterior portion of the THORAX. The breasts consist of the MAMMARY GLANDS, the SKIN, the MUSCLES, the ADIPOSE TISSUE, and the CONNECTIVE TISSUES.Hepatitis B Surface Antigens: Those hepatitis B antigens found on the surface of the Dane particle and on the 20 nm spherical and tubular particles. Several subspecificities of the surface antigen are known. These were formerly called the Australia antigen.Blood Urea Nitrogen: The urea concentration of the blood stated in terms of nitrogen content. Serum (plasma) urea nitrogen is approximately 12% higher than blood urea nitrogen concentration because of the greater protein content of red blood cells. Increases in blood or serum urea nitrogen are referred to as azotemia and may have prerenal, renal, or postrenal causes. (From Saunders Dictionary & Encyclopedia of Laboratory Medicine and Technology, 1984)Platelet Count: The number of PLATELETS per unit volume in a sample of venous BLOOD.Nuclear Medicine: A specialty field of radiology concerned with diagnostic, therapeutic, and investigative use of radioactive compounds in a pharmaceutical form.Carcinoma, Lobular: A infiltrating (invasive) breast cancer, relatively uncommon, accounting for only 5%-10% of breast tumors in most series. It is often an area of ill-defined thickening in the breast, in contrast to the dominant lump characteristic of ductal carcinoma. It is typically composed of small cells in a linear arrangement with a tendency to grow around ducts and lobules. There is likelihood of axillary nodal involvement with metastasis to meningeal and serosal surfaces. (DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1205)Occupational Therapy: Skilled treatment that helps individuals achieve independence in all facets of their lives. It assists in the development of skills needed for independent living.Internship and Residency: Programs of training in medicine and medical specialties offered by hospitals for graduates of medicine to meet the requirements established by accrediting authorities.Biological Science Disciplines: All of the divisions of the natural sciences dealing with the various aspects of the phenomena of life and vital processes. The concept includes anatomy and physiology, biochemistry and biophysics, and the biology of animals, plants, and microorganisms. It should be differentiated from BIOLOGY, one of its subdivisions, concerned specifically with the origin and life processes of living organisms.Internship, Nonmedical: Advanced programs of training to meet certain professional requirements in fields other than medicine or dentistry, e.g., pharmacology, nutrition, nursing, etc.Northwest Territories: A federally administered division of Canada. Its capital is Yellowknife. The former northern and eastern-most parts of the Territory comprise the new territory of Nunavut, effective April 1, 1999.Curriculum: A course of study offered by an educational institution.Questionnaires: Predetermined sets of questions used to collect data - clinical data, social status, occupational group, etc. The term is often applied to a self-completed survey instrument.

New treatment strategies for malignant gliomas. (1/231)

Although survival in patients with malignant gliomas remains limited, there is renewed optimism with the emergence of novel treatment strategies. Cytotoxic agents such as temozolomide and CPT-11 have shown promising clinical activity. Biological treatments for brain tumors, including antisense oligonucleotides, gene therapy, and angiogenesis inhibitors, are also being evaluated in clinical trials. Delivery strategies have been developed to overcome challenges presented by the blood-brain barrier. These noteworthy treatments, alone or in combination, may ultimately prolong survival and enhance quality of life in this group of patients.  (+info)

Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. (2/231)

Genetically engineered, neuroattenuated herpes simplex viruses (HSVs) expressing various cytokines can improve survival when used in the treatment of experimental brain tumors. These attenuated viruses have both copies of gamma(1)34.5 deleted. Recently, we demonstrated increased survival of C57BL/6 mice bearing syngeneic GL-261 gliomas when treated with an engineered HSV expressing IL-4, as compared with treatment with the parent construct (gamma(1)34. 5(-)) alone or with a virus expressing IL-10. Herein, we report construction of a conditionally replication-competent mutant expressing both subunits of mIL-12 (M002) and its evaluation in a syngeneic neuroblastoma murine model. IL-12 induces a helper T cell subset type 1 response, which may induce more durable antitumor effects. In vitro studies showed that, when infected with M002, both Vero cells and murine Neuro-2a neuroblastoma cells produced physiologically relevant levels of IL-12 heterodimers, as determined by ELISA. M002 was cytotoxic for Neuro-2a cells and human glioma cell lines U251MG and D54MG. Neurotoxicity studies, as defined by plaque-forming units/LD(50), performed in HSV-1-sensitive A/J strain mice found that M002 was not toxic even at high doses. When evaluated in an intracranial syngeneic neuroblastoma murine model, median survival of M002-treated animals was significantly longer than the median survival of animals treated with R3659, the parent gamma(1)34.5(-) mutant lacking any cytokine gene insert. Immunohistochemical analysis of M002-treated tumors identified a pronounced influx of CD4(+) T cells and macrophages as well as CD8(+) cells when compared with an analysis of R3659-treated tumors. We conclude that M002 produced a survival benefit via oncolytic effects combined with immunologic effects meditated by helper T cells of subset type 1.  (+info)

Where is biological therapy going? (3/231)

The substantial progress in our understanding of molecular and cellular biology has allowed us to design biological therapeutics ('biologicals') with defined targets and effector functions. These biologicals have greatly contributed to our current knowledge of pathogenetic mechanisms in autoimmune diseases. However, although some of the biologicals have been extremely successful in treating the symptoms of chronic inflammation, biological therapy has not yet met the expectations of permanently silencing the chronic immune response. In this commentary we discuss current concepts and future directions of biological therapy, and the potential usefulness of biologicals as a treatment of human autoimmune diseases in appropriate critical applications with the use of suitably designed agents.  (+info)

Probiotic agents and infectious diseases: a modern perspective on a traditional therapy. (4/231)

There is an increasing scientific and commercial interest in the use of beneficial microorganisms, or "probiotics," for the prevention and treatment of disease. The microorganisms most frequently used as probiotic agents are lactic-acid bacteria such as Lactobacillus rhamnosus GG (LGG), which has been extensively studied in recent literature. Multiple mechanisms of action have been postulated, including lactose digestion, production of antimicrobial agents, competition for space or nutrients, and immunomodulation. We have reviewed recent studies of probiotics for the treatment and control of infectious diseases. Studies of pediatric diarrhea show substantial evidence of clinical benefits from probiotic therapy in patients with viral gastroenteritis, and data on LGG treatment for Clostridium difficile diarrhea appear promising. However, data to support use of probiotics for prevention of traveler's diarrhea are more limited. New research suggests potential applications in vaccine development and prevention of sexually transmitted diseases. Further studies are needed to take full advantage of this traditional medical approach and to apply it to the infectious diseases of the new millennium.  (+info)

Update on the treatment of systemic lupus erythematosus: therapeutic highlights from the Sixth International Lupus Conference. (5/231)

The studies presented at the conference indicate that new therapeutic agents are effective for patients with SLE. Some of the agents (high dose cyclophosphamide) may be given to patients with refractory disease while others (low dose cyclophosphamide, and MMF) may be used as a first-line drug. The current data on biologic agents are still preliminary and their exact role in SLE needs to be determined.  (+info)

The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy. (6/231)

BACKGROUND: Gemcitabine and vinorelbine are two of the most active third-generation agents for the treatment of advanced nonsmall cell lung carcinoma (NSCLC). The authors conducted a formal Phase II trial to evaluate the efficacy of this combination in both untreated and previously treated patients with Stage IIIB (with pleural effusion) or Stage IV NSCLC. METHODS: A total of 78 patients were treated on the current Phase II trial of front-line or second/third-line therapy with gemcitabine and vinorelbine in NSCLC. Eligible patients manifested either untreated disease (n = 42) or had received at least one but not more than two prior chemotherapy regimens (n = 36). The median age was 57.5 years (range, 33-79) with 57 men (73%) and 21 women (27%). The median performance status was one (range, one to two). The initial eight patients (four untreated and four previously treated) were treated at a previously established maximum tolerated dose of vinorelbine (30 mg/m(2)) and gemcitabine (1000 mg/m(2)) on Days 1, 8, and 15, with significant myelosuppression seen in five out of eight patients requiring dose omission in the first cycle. The next 70 patients received a reduced dose of vinorelbine (25 mg/m(2)) followed by gemcitabine (900 mg/m(2)) on Days 1, 8, and 15. RESULTS: Seventy eight patients were treated. Fifteen (36%) of the 42 evaluable patients who received front-line therapy had objective responses and 14 (33%) had stable disease. In the patients with prior treatment, 6 (17%) of 36 patients had partial response and 18 patients (50%) had stable disease. Median survival time for the previously untreated patient group was 10.1 months, with a one year survival of 43% and a two year survival rate of 32%. For the previously treated patients, the median survival time was 8.5 months, with a one year survival rate of 30%. Toxic effects were notable for significant myelosuppression, with > or =Grade 3 granulocytopenia seen in 55% of the patients on the untreated arm and 67% of the patients on the previously treated arm. Additionally, 9.5% and 13.9% (untreated and previously treated), respectively, of these patients experienced Grades 3 and 4 thrombocytopenia at some point in their treatment. A full dose delivery analysis showed that this myelosuppression resulted in Course 1, Day 15 skipped doses (even at the reduced dose level) in 42% of previously untreated patients and 47% of pretreated patients. Other side effects seen at Grades 3 and 4 in previously untreated and treated patients included anemia (9.5% and 2.8%), asthenia (4.8% and 5.5%), infection (14.3% and 5.6%), pain (9.5% and 19.4%), and pulmonary complications (4.8% and 13.8%). CONCLUSIONS: Gemcitabine/vinorelbine is an active, well-tolerated combination in both front-line and second/third-line therapy for Stage IIIB/IV NSCLC. The response rate, median survival rate, and one year survival rate compare favorably with platinum-based regimens. The toxicity profile of the gemcitabine/vinorelbine combination was quite favorable, with minimal Grade 3 and 4 toxic effects aside from granulocytopenia, which resulted in numerous Day 15 skipped doses but no significant febrile neutropenia or infection. The combination of gemcitabine and vinorelbine could be a useful regimen in standard clinical practice and has the potential for efficient combination with biologic/targeted therapy. Multiple randomized trials of this combination versus platinum combinations are now ongoing [corrected].  (+info)

Yoghurt biotherapy: contraindicated in immunosuppressed patients? (7/231)

A fatal case of Lactobacillus rhamnosus septicaemia after prolonged oral vancomycin for recalcitrant Clostridium difficile infection is reported. The patient was immunosuppressed with cyclophosphamide and steroids for Sjogren's syndrome. The administration of Lactobacillus spp as "biotherapy" may be hazardous in such circumstances.  (+info)

Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker. (8/231)

Live attenuated measles virus (MV-Edm) has potent oncolytic activity against myeloma xenografts in mice. Therapy of multiple myeloma, a disseminated plasma cell malignancy, would require systemic administration of the virus. Thus, the virus should ideally be targeted to infect only myeloma cells to minimize collateral damage to normal tissues: viral binding to its natural receptors must be ablated and a new specificity domain that targets entry into myeloma cells be added. This study covers 2 critical steps toward generating such a retargeted virus: (1) a new specificity domain against the plasma cell marker CD38 was constructed in the form of a single-chain antibody (scFv) and (2) display of that scFv on the measles viral envelope glycoprotein successfully redirected virus entry through CD38 expressed on target cells devoid of the natural MV receptors. The anti-CD38 scFv was tethered to the C-terminus of the hemagglutinin (H) glycoprotein of MV-Edm through a Factor Xa protease cleavable linker. Immunoblot analysis demonstrated that the scFv was efficiently incorporated into recombinant viral particles. Replication of MV-alpha CD38 was not hindered by the scFv, reaching titers comparable to MV-Edm. Chinese hamster ovary (CHO) cells were resistant to infection by MV-Edm and MV-alpha CD38. In contrast, CHO cells expressing CD38 became susceptible to infection by MV-alpha CD38 but not MV-Edm. Removal of the displayed scFv rendered MV-alpha CD38 noninfectious on CHO-CD38 cells. Tumorigenicity of CHO-CD38 cells in immunocompromised mice was significantly attenuated by MV-alpha CD38, resulting in enhanced survival of these mice compared with the control group.  (+info)

Mark Davis, ND. Fecal microbiota transplantation (FMT) is also known as human probiotic infusion, fecal transplant, fecal bacteriotherapy, fecal slurry, and gut flora rehabilitation and has been humorously referred to as "transpoosion." The procedure consists of collecting stool from a healthy donor; suspending it in water, normal saline, or 4% milk; and administering it to the patient (most frequently via enema but also via colonoscope, nasogastric or nasoduodenal tube, rectal tube, or even [anecdotally] orally as a milkshake1). This massive infusion of healthy colonic bacteria has been used as far back as the 17th century in veterinary medicine to treat digestive disturbances2 and as early as 1958 in humans to treat pseudomembranous colitis.3. Fecal microbiota transplantation has a 90% success rate in curing Clostridium difficile-associated chronic diarrhea, colitis, and pseudomembranous colitis,4 which affect half a million and kill 15 000 to 20 000 Americans per year.5 Fecal microbiota ...
The investigators propose to use autologous fecal microbiota transplantation (AFMT) to acute myeloid leukemia (AML) patients treated with intensive chemotherapy and antibiotics in order to restore the balance of their intestinal microbiome and thereby eradicate treatment-induced multidrug resistant bacteria (MDRB), infection-related complications, as well as sequelae to the gastrointestinal tract. Therefore, the investigators propose to perform a single-arm multicentre prospective fecal microbiota transplantation (FMT) trial in AML patients receiving intensive chemotherapy, and who are usually heavily treated with broad-spectrum antibiotics during aplasia that generate a profound status of dysbiosis. For this purpose, at the time of admission and AML diagnosis, patients will be requested to donate stools that will be comprehensively screened, and if deemed appropriate according to protocol criteria, conditioned and stored frozen until future processing and transplantation after aplasia completion ...
Dysbiosis plays a major role in the etiology of inflammatory bowel disease (IBD). Fecal microbiota transplantation (FMT) is a new promising option for IBD treatment. We aimed to assess the effectivene
Phys.org Science News Wire : Largest Planned Fecal Microbiota Transplantation (FMT) study enrolls first patient -- a press release is provided to you ìas isî with little or no review from Phys.org staff.
We established a standard bacteria isolation from donated fresh stool in lab.Then the bacteria is transplanted to mid-gut (at least below the second part of duodenum ) through regular gastroscope. Participants in this study will be randomly assigned to receive fecal microbiota transplantation only once or traditional therapy, and accept follow-up for at least one year. Blood tests,OGTT and magnetic resonance spectroscopy will be used to assess participants at study start and at study completion ...
Biological therapies in the systemic management of psoriasis; International Consensus Conference. Br J Dermatol, 151 (2004), pp. 3-17. Medline. 4. D. Thaci. Cosentyx is the only biologic that can be used as first-line systemic therapy in the treatment of psoriasis and as an alternative to treatments that have significant side effects 1; all other biologics are recommended for second-line therapy 2-4. Currently, all biologic treatments for psoriasis, including anti-tumor necrosis factor therapies (anti-TNFs) and Stelara (ustekinumab) are recommended for second-line systemic therapy in Europe 2-4. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Article September 2004 British Journal of Dermatology. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol. 2004;151 Suppl 69:3-17. Biologic agents ...
Biological therapy is a treatment that uses your bodys immune system to fight cancer cells rather than attacking those cells directly. For carefully selected people, biological therapy may target cancer cells to avoid damage to normal cells, prevent or slow tumor growth, and prevent the spread of cancer cells. Although it can have side effects, typically this type of therapy is less invasive and less toxic than conventional cancer treatments are. Biological therapy for cancer includes immunotherapy, targeted therapy and therapy that inhibits the growth of blood vessels (anti-angiogenesis).
Biological therapy is used treat certain types of non-Hodgkin lymphoma. Learn how and when biological therapy is used and side effects of biological therapy.
FMT as a treatment modality has also been tested in a range of other diseases, such as inflammatory bowel disease (IBD), irritable bowel syndrome, obesity and metabolic syndrome, as well as neurological and psychological disorders, although most reports of the latter category are merely anecdotal. Yet, the results so far are not convincing. Reports about using FMT to treat IBD patients show considerable heterogeneity in terms of clinical effect (Moayyedi et al, 2015), whereas efficacy in patients with metabolic syndrome was transient. Insulin resistance improved 6 weeks after the FMT, but at 12 weeks, no significant effect was observed anymore on metabolic parameters and fecal microbiota composition (Vrieze et al, 2012).. The reason why FMT has such variable efficacy is probably due to the stability and resilience of the gut microbiota. CDI patients who have been treated multiple times with antibiotics have most of their bacterial diversity wiped out; FMT effectively repopulates this vacated ...
Clin Gastroenterol Hepatol. 2011 Dec;9(12):1044-9. doi: 10.1016/j.cgh.2011.08.014. Epub 2011 Aug 24. Research Support, N.I.H., Extramural; Research Support, Non-U.S. Govt; Review
Key takeaways from Randi Lundbergs review of the pros and cons of using antibiotic-treated or germ-free mice in fecal microbiota transplant studies.
Introduction. There is a growing body of evidence highlighting the possible interactions between the microbiota and cancer. However, little is known about the consequence on the microbiota of the intensive chemotherapy in patients with AML. Indeed, intensive treatments of AML are known to negatively impact gut microbiota composition; it is measured by a deep shutdown of diversity indices (eg. Simpson), also called dysbiosis. Decrease in microbiota diversity may impact the immune system and may have consequences on the outcome of AML patients. Therefore, development of strategies to manipulate the gut microbiota may minimize treatment-related complications and potentially improve outcomes. With this background, we developed a single arm prospective phase I/II multicenter trial (ClinicalTrials.gov Identifier: NCT02928523) aiming to evaluate use of auto-FMT in AML patients treated with intensive chemotherapy and antibiotics. Patients and methods. For this purpose, at the time of admission and AML ...
Key Points. Bacterial diversity was restored after FMT with oral frozen capsules, with improvement of diarrhea.Oral FMT for steroid-refractory acute gGVHD is f
Professor Borody is most famous for his ground-breaking work developing the triple therapy cure for peptic ulcers in 1987, which has saved hundreds of thousands…
Gastroenterology & Hepatology. January 2015, Volume 11, Issue 1. Woo Jung Lee, MD, Lakshmi D. N. Lattimer, MD, Sindu Stephen, MD, Marie L. Borum, MD, and David B. Doman, MD. Dr Lee and Dr Lattimer are gastroenterology fellows in the Division of Gastroenterology and Liver Diseases at George Washington University Medical Center and are affiliated with Medical Faculty Associates, both in Washington, DC. Dr Stephen is a gastroenterologist in Silver Spring, Maryland. Dr Borum is a professor of medicine at George Washington University School of Medicine in Washington, DC and the director of the Division of Gastroenterology and Liver Diseases at George Washington University Medical Center; she is also affiliated with Medical Faculty Associates. Dr Doman is a clinical professor of medicine at George Washington University School of Medicine.. Address correspondence to: Dr David B. Doman, 12012 Veirs Mill Road, Silver Spring, MD 20906, Tel: 301-942-3550, E-mail: [email protected] Abstract: The symbiotic ...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Excision BioTherapeutics, a life science company focused on the development and commercialization of advanced gene editing therapeutics for the treatment of life-threatening disease caused by neurotropic viruses, recently announced it has completed a $10 million seed round of financing, led by ARTIS Ventures. The investment will enable the company to enter into human clinical trials with its HIV-1 targeted CRISPR platform, giving Excision BioTherapeutics the first effort to fully remove/excise the HIV-1 genome from all human cells and tissues. In addition, Excision BioTherapeutics is extending this approach to other viruses by targeting their genetic elements, and eliminating them permanently from the patient. Regarding this development, Thomas Malcolm, Ph.D, Excision BioTherapeutics founder, president and CEO, stated "Excisions mission has always been to advance gene editing therapeutics into safe and efficacious medicines that will eradicate or disrupt viral genes in human patients. The ...
Biological therapy (also called immunotherapy, biological response modifier therapy, or biotherapy) uses the bodys immune system to fight cancer. The cells, antibodies, and organs of the immune system work to protect and defend the body against foreign invaders, such as bacteria or viruses. Doctors and researchers have found that the immune system might also be able to both determine the difference between healthy cells and cancer cells in the body, and to eliminate the cancer cells. (By itself, the immune system is not always good at destroying cancer cells; if it were, people would not get cancer.). Biological therapies are designed to boost the immune system, either directly or indirectly, by assisting in the following:. ...
Kaltsonoudis et al.9 conducted a prospective study in 77 patients with inflammatory rheumatic disease (36 patients with rheumatoid arthritis, 24 patients with psoriatic arthritis and 17 patients with ankylosing spondylitis) who began with anti-TNFα (infliximab, adalimumab, etanercept). All underwent a complete neurological examination, nuclear magnetic resonance of the brain and the entire spine, and a neurophysiology study before and more than 18 months after starting the biological therapy. In the initial scrutiny, they detected lesions compatible with demyelinating disease in magnetic resonance in 2 patients and, thus, decided against the biological treatment. At the end of the study, 4% of the patients (3/75) showed evidence of neurological involvement: peripheral demyelinating neuropathy (2 patients) and optic neuritis. In each case, the biological therapy was interrupted and the neurological disease was treated. The neurological symptoms remitted in all the patients.9 The authors stress ...
Patients with inflammatory bowel disease who required abdominal surgery while on biologics did not have more postoperative complications than those whose biologic regimens were interrupted.13-15. The first study of patients with psoriasis or psoriatic arthritis on biologics enrolled 42 patients undergoing 77 different procedures.16 While patients who continued biologic therapy did not have higher rates of postoperative complications, those who did interrupt treatment found their underlying disease worsened. Most rheumatology associations recommend interrupting biologic therapy for at least 4 half-lives before scheduled major surgery; that criterion would involve going 4 to 6 weeks without infliximab, 6 to 8 weeks off adalimumab, 2 to 3 weeks off etanercept, and 12 to 25 weeks off ustekinumab before operations.17-19 The evidence supporting that recommendation, however, is weak; in fact, it is supported only by expert opinion.. The 2013 consensus statement of the Spanish Academy of Dermatology and ...
Looking for information on Biologic Therapies for Aging Discs in Bellaire? We have compiled a list of businesses and services around Bellaire that should help you with your search. We hope this page helps you find information on Biologic Therapies for Aging Discs in Bellaire.
Looking for information on Biologic Therapies for Aging Discs in Fairmont? We have compiled a list of businesses and services around Fairmont that should help you with your search. We hope this page helps you find information on Biologic Therapies for Aging Discs in Fairmont.
Global Cancer Biologic Therapy Market- Forecast to 2021 The report firstly introduced Global Cancer Biologic Therapy Market including classification, appli
Biological therapy may be used to treat chronic myelogenous leukemia in the chronic or accelerated phase. Learn about biological therapy for CML.
Phage therapy or viral phage therapy is the therapeutic use of bacteriophages to treat pathogenic bacterial infections. Phage therapy has many potential applications in human medicine as well as dentistry, veterinary science, and agriculture. If the target host of a phage therapy treatment is not an animal, the term "biocontrol" (as in phage-mediated biocontrol of bacteria) is usually employed, rather than "phage therapy". Bacteriophages are much more specific than antibiotics. They are typically harmless not only to the host organism, but also to other beneficial bacteria, such as the gut flora, reducing the chances of opportunistic infections. They have a high therapeutic index, that is, phage therapy would be expected to give rise to few side effects. Because phages replicate in vivo, a smaller effective dose can be used. On the other hand, this specificity is also a disadvantage: a phage will only kill a bacterium if it is a match to the specific strain. Consequently, phage mixtures are ...
...FORT WORTH Texas June 7 2011 /- Healthpoint Biotherape...The presentations will include updates on the Companys ongoing commer... About Healthpoint Biotherapeutics ...Healthpoint Biotherapeutics is a biopharmaceutical company focused on ...,Healthpoint,Biotherapeutics,to,Present,at,Upcoming,Investment,Conferences,medicine,advanced medical technology,medical laboratory technology,medical device technology,latest medical technology,Health
Title: Phage Therapy in Clinical Practice: Treatment of Human Infections. VOLUME: 11 ISSUE: 1. Author(s):Elizabeth Kutter, Daniel De Vos, Guram Gvasalia, Zemphira Alavidze, Lasha Gogokhia, Sarah Kuhl and Stephen T. Abedon. Affiliation:Lab 1, The Evergreen State College, Olympia, WA 98505, USA.. Keywords:Bacteriophages, burn care, Eliava Institute, Hirszfeld Institute, intestiphage, osteomyelitis treatment, phage therapy, purulent infections, pyophage, wound care. Abstract: Phage therapy is the application of bacteria-specific viruses with the goal of reducing or eliminating pathogenic or nuisance bacteria. While phage therapy has become a broadly relevant technology, including veterinary, agricultural, and food microbiology applications, it is for the treatment or prevention of human infections that phage therapy first caught the worlds imagination - see, especially, Arrowsmith by Sinclair Lewis (1925) - and which today is the primary motivator of the field. Nonetheless, though the first human ...
Bacteriotherapy is the use of transplanted bacteria inside of an organism. Fecal bacteriotherapy works due to bacterial interference, the process by which bacteria displace pathogens. Bioremediation Biodegradation Microbial biodegradation van Nood, E; Vrieze, A; Nieuwdorp, M; et al. (January 2013). "Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile". N. Engl. J. Med. 368 (5): 407-15. doi:10.1056/NEJMoa1205037. PMID 23323867. Huovinen, Pentti (18 August 2001). "Bacteriotherapy: the time has come". British Medical Journal. BMJ Group. 323 (7309): 353-354. doi:10.1136/bmj.323.7309.353. PMC 1120965 . PMID 11509411 ...
Fecal bacteriotherapy Fecal microbiota transplantation (FMT) also known as a stool transplant is the process of transplantation of fecal bacteria...
This long overdue title provides a comprehensive, up-to-date, state-of-the art review of approved biologic therapies, with coverage of mechanisms of action, Indications for therapy, immunogenicity and a detailed examination of adverse effects and safety of the many and diverse therapeutic agents presented in a total of 13 chapters. It is predicted that by 2016, biologics will make up half of the worlds 20 top-selling drugs and by 2018, biologic medicine sales will account for almost half of the worlds 100 biggest selling drugs. Recombinant proteins dominate the growing list of the more than 200 approved biotherapeutic agents with targeted antibodies, fusion proteins and receptors; cytokines; hormones; enzymes; proteins involved in blood-clotting, homeostasis and thrombosis; vaccines; botulinum neurotoxins; and, more recently, biosimilar preparations, comprising the majority of approved biologics. Written with clinicians, other health care professionals, and researchers in mind, Safety of ...
Rectal bacteriotherapy, fecal microbiota transplantation or oral vancomycin treatment of recurrent Clostridium difficile infections: A randomized controlled trial. ...
Our Biologic Therapy Program focuses on the treatment of advanced melanoma and kidney cancer. Physicians, including Drs. Michael Atkins, David McDermott, James Mier, Rupal Bhatt, and Dan Cho, investigate and use biologic agents, such as cytokines and vaccines, to treat solid tumors in patients with metastatic melanoma and kidney carcinoma.
Title:Recent Advances in Probiotics as Live Biotherapeutics Against Gastrointestinal Diseases. VOLUME: 24 ISSUE: 27. Author(s):Rohini Krishna Kota, Ranga Rao Ambati*, Aswani Kumar Y.V.V., Krupanidhi Srirama and Prakash Narayana Reddy*. Affiliation:Department of Biotechnology, Vignans Foundation for Science, Technology and Research, Vadlamudi, Guntur-522213, Andhra Pradesh, Department of Biotechnology, Vignans Foundation for Science, Technology and Research, Vadlamudi, Guntur-522213, Andhra Pradesh, Department of Biotechnology, Acharya Nagarjuna University Nagarjuna Nagar, Guntur- 522510, Andhra Pradesh, Department of Biotechnology, Vignans Foundation for Science, Technology and Research, Vadlamudi, Guntur-522213, Andhra Pradesh, Department of Biotechnology, Vignans Foundation for Science, Technology and Research, Vadlamudi, Guntur-522213, Andhra Pradesh. Keywords:Gastrointestinal diseases, therapy, probiotics, biotherapeutics, Fecal Microbial Transplants (FMTs), Gut microbiota ...
BETHESDA, MD, January 18, 2017 - Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable and inoperable solid tumor cancers, announced today that Dr. Marnix Bosch, Chief Technical Officer of NW Bio, will present at the Phacilitate Immunotherapy World Conference on Thursday, January 19, 2017, at the Hyatt Regency Hotel in Miami, Florida.. Dr. Bosch will chair the session entitled "New Therapeutic Approaches - Expanding the Reach of Cancer Immunotherapy to All Patients In Need of Better Treatments," taking place from 4:30 p.m. to 5:35 p.m. on Thursday, January 19, and will make a presentation on the same subject. There will not be a webcast. The presentation was originally scheduled to be made by Ms. Linda Powers, CEO of NW Bio, but she was unable to do so due to illness.. The annual Phacilitate Immunotherapy World Forum is one of the worlds largest and fastest growing senior-level immuno-oncology ...
Funding Enables Existing Clinical Trials to Proceed as Company Joins Global Response with COVID-19 Program. PITTSBURGH - May 7, 2020 - Noveome Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing next-generation biologics for the promotion and restoration of cellular integrity of inflamed or damaged tissues, has received a $4 Million grant from the Commonwealth of Pennsylvania to continue clinical trials of its lead product candidate, ST266, in a wide range of diseases, including multiple ophthalmic indications. The funding will enable Noveome to shift its existing resources to support the companys recently launched COVID-19 program evaluating ST266 as a treatment for the "cytokine storm"-the severe inflammatory response often observed in COVID-19 infections.. "While researchers around the world race to deliver a vaccine that will address this COVID-19 pandemic head on, we need a range of new therapeutics and diagnostics to stem the tide. This very timely funding will ...
3 Cases Substantially Completed, 4th Case Pending Completion, No Monetary Damages Contemplated. Bethesda, MD, October 24, 2017 - Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable and inoperable solid tumor cancers, is pleased to report meaningful progress in resolving four lawsuits that were brought against it as reported in the Companys periodic filings.. All four of the lawsuits have been or are being resolved without any negative findings against the Company or its management, despite allegations of misconduct and misrepresentation, and resolved without any monetary damages. One of the cases was dismissed outright, in its entirety, by the court. Two further cases were settled after NW Bio announced the Nasdaq remediation plan on September 6, 2016 and agreed to take certain future actions to enhance its corporate governance practices. The fourth case is in the process of being settled on similar ...
...DURHAM N.C. Dec. 14 /- Oxygen Biotherapeutics...Dr. Blanck began his military career in 1968 as a medical officer and ...After his military service and prior to joining Martin Blanck & A... I am very honored that an individual with Ron Blancks combination of...,Oxygen,Biotherapeutics,,Inc.,Expands,Board,of,Directors,medicine,advanced medical technology,medical laboratory technology,medical device technology,latest medical technology,Health
Results 22 women and 8 men mainly living in urban areas (73.3%) and most of them with at least 12 years of formal education (73.3%) have been included in the study. Mean age was 56.8 (sd: 12.7) years and mean duration on biological therapy was 49 (20.2) months. In 22 cases (73.3%) patients received a new treatment because of the lack of efficacy of the previous one, in two cases it was an allergic reaction and in 6 cases (20%) an administrative reason determined this change. The aspects our patients considered as being most important when select a 2nd biologic are: the efficacy of new drug compared with the previous one, treatment schedule, the impact of new treatment on previous comorbidities, the global efficacy of new drug. On the opposite side are: the route of administration, the potential role of a health worker in drug administration, the possible financial aid (co-reimbursement) schemes. We also evaluated how deep every of these 24 aspects have been discussed with the rheumatologists at ...
Results Of the total of patients, 24/37 (64.9%) were treated with Ifx and 13/37 (35.1%) with Ada, being female 23 (62.1%). The mean age was 55.1 ± 12.3 years and the mean disease duration was 14.4 ± 9.9 years. The average time on biological therapy was 4.4 ± 3.2 years. Most patients received concomitantly classical DMARDs [29/37 (78.3%) with DMARDs vs 8/37 (21.7%) in monotherapy]. At baseline, clinical activity (DAS28) was higher in patients who subsequently not developed ADA (5.1 ± 0.9 without ADA vs 13.4 ± 0.6 with ADA, p = 0.021). Clinical activity (DAS28) tended to be higher in patients with ADA at all studied time points (5.4 ± 1.2 with ADA vs 2.8 ± 1.3 without ADA at 6 months, p = 0.007; 4.0 ± 1.2 with ADA vs 3.0 ± 1.3 without ADA at 1 year, p = 0.144; 2.9 ± 1.3 with ADA vs 2.4 ± 0.4 without ADA a, 2nd year, p = 0.169). Clinical improvement (delta-DAS28) was lower in patients with ADA throughout the study (-1.0 ± 1.6 with ADA vs 2.0 ± 1.4 without ADA at 6 months, p = 0.006, ...
Black patients receiving Medicare are less likely to receive biologic therapies for the treatment of moderate to severe psoriasis than white patients.
An update on the use of biologic therapies in the management of uveitis in Behçets disease: a comprehensive review. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
Immunotherapy, or biological therapy, uses the bodys immune system to fight cancer and other diseases. Learn more about immunotherapy treatment at Virtua.
Benefits of biologic therapy for inflammatory diseases such as psoriasis, psoriatic arthritis, etc outweigh the risk for developing infections like tuberculosis, shingles, pneumonia and listeriosis.
Common side effects of biological therapies are generally similar to flu symptoms. These include fever, chills, fatigue, headache, and muscle aches. Biological therapy may also cause rash or swelling where the injection is given. Symptoms may differ, depending on the person and the therapy. Medications may be given to prevent side effects of biological therapy. Side effects usually stop when treatment is finished.. Interferon alpha may affect the bone marrow or the liver. Interleukin-2 can cause a drop in blood pressure and a build-up of fluid in your body. Yervoy™ (ipilimumab) may cause immune system side effects. All biological therapies should be used with caution based on their potential toxicities.. ...
Cancer Monthly. Lung Cancer treatments. Biologic therapy. Chemotherapy. Mount Sinai Cancer Center, Miami Beach, FL, United States. Compare therapy differences, longest survival rates, toxicity, side effects, hospitals.
Cancer Monthly. Breast Cancer treatments. Biologic therapy. Chemotherapy. Monash University, Clayton, Australia. Compare therapy differences, longest survival rates, toxicity, side effects, hospitals.
The major growth drivers for Biologic Therapy includes the increasing pharmaceuticals industries, increasing biologic products increasing government suppor
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining different types of biolo
RATIONALE: Biological therapy using a gene-modified virus that can make interleukin-12 may help the body build an effective immune response to kill tumo
This book offers psychiatry residents and other mental health professionals an introduction to the combined use of psychological and biological therapies in managing common psychiatric disorders.
People searching for Bachelors Degree in Biological Therapy found the following resources, articles, links, and information helpful.
Biological therapies can be defined as targeted therapies used to attack a particular protein, enzyme or other cellular component. Click here to read more.
INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. announced today that it has entered into a strategic collaboration agreement with Takeda Pharmaceutical Company Limited (TSE: 4502) to jointly fund and co-develop multiple novel biologic therapies in unmet disease areas. The two companies will immediately begin
Regular use of phage therapy occurs primarily in the Republic of Georgia, due to the presence of the Eliava Institute, which has research phage therapy since the 1920s. However, synthetic biology has enabled entirely new approaches to phage therapy, such as engineering new abilities into the phage. One such ability is the degradation of the extracellular polysaccharides (EPS) produced by bacteria during infections[2]. Production of the EPS results in a biofilm, which protects the bacteria within from external harm, such as antibiotics and bacteriophages, limiting the damage to the cells on the surface. To break through this barrier, researches inserted the gene for DspB, an enzyme that degrades one of the key components of EPS. After bacteria on the surface of the biofilm are infected, they produce DspB along with new phage. After the cells lyse, the DspB can degrade the EPS, which exposes more bacteria to infection. One concern of phage therapy is the rapid lysing of pathogenic cells which may ...
OBJECTIVES/SPECIFIC AIMS: Clostridium difficile infection (CDI) is the most common cause of antibiotic-associated diarrhea and an increasingly common infection in children in both hospital and community settings. Between 20% and 30% of pediatric patients will have a recurrence of symptoms in the days to weeks following an initial infection. Multiple recurrences have been successfully treated with fecal microbiota transplantation (FMT), though the body of evidence in pediatric patients is limited primarily to case reports and case series. The goal of our study was to better understand practices, success, and safety of FMT in children as well as identify risk factors associated with a failed FMT in our pediatric patients. METHODS/STUDY POPULATION: This multicenter retrospective analysis included 373 patients who underwent FMT for CDI between January 1, 2006 and January 1, 2017 from 18 pediatric centers. Demographics, baseline characteristics, FMT practices, C. difficile outcomes, and post-FMT ...
RATIONALE: High-salt diet is one of the most important risk factors for hypertension. Intestinal flora has been reported to be associated with high salt-induced hypertension (hSIH). However, the detailed roles of intestinal flora in hSIH pathogenesis have not yet been fully elucidated. OBJECTIVE: To reveal the roles and mechanisms of intestinal flora in hSIH development. METHODS AND RESULTS: The abovementioned issues were investigated using various techniques including 16S rRNA gene sequencing, untargeted metabolomics, selective bacterial culture, and fecal microbiota transplantation. We found that high-salt diet induced hypertension in Wistar rats. The fecal microbiota of healthy rats could dramatically lower blood pressure (BP) of hypertensive rats, whereas the fecal microbiota of hSIH rats had opposite effects. The composition, metabolism, and interrelationship of intestinal flora in hSIH rats were considerably reshaped, including the increased corticosterone level and reduced Bacteroides and ...
While fecal microbiota transplantation (FMT) was associated with fewer bloodstream infections than antibiotics in one study, a brief report described two cases of drug-resistant bacteremia transmitted by FMT.
Borody, T.J., Leis, S., Pang, G., & Wettstein, A.R. (2013). Fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection. In T.W. Post, P. Rutgeerts, & S. Grover (Eds.), UptoDate. Available from https://arch.library.nyu.edu/databases/proxy/NYU04665. [use Available from to indicate that the URL will lead users to a download site rather than directly to the chapter.]. ...
A study in this weeks issue of the Journal of the American Medical Association compares frozen with fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection ...
Fecal microbiota transplantation (FMT) is a successful, albeit disgusting way to cure gastrointestinal diseases. It is also being tested to treat other illnesses. FMT helps replace beneficial gut bacteria whose numbers have been reduced in the microbiome of the human colon.
Last Fall I went to Sydney Australia on a vacation and while I was there I looked into their programs and research. I found FMT. Fecal Microbiota Transplantation. I was grossed out and said oh hell no. Still, the more I studied and read the more it seemed worth a try. So, I called my doctor here and asked if I could be in one of the clinical studies. Unfortunately there wasnt one here. Only in Portland Oregon. He happened to know the doctor running the study though and offered me another way to treat myself at home. My husbands stool was tested for HIV, Hep A B and C, C Diff, and he passed all the tests with flying colors. So, we bought a retention nozzle, enema bag, tons of Zip lock freezer bags, went through training with our nurses so he could help me complete the series of enemas and my flora was checked and measured by my doctor every other week 7 days after each treatment. I was really sore down there from all the surgeries so instead of 7 days of back to back enemas we changed it to once ...
Septembers issue of Alimentary Pharmacology & Therapeutics investigates fecal microbiota transplantation in the management of inflammatory bowel disease.. ...
R. Hsu. Chapter editor for Crohns disease and Ulcerative Colitis - StatPearls On-line peer reviewed CME/CE medical library. 2016.. R. Hsu, N. Stollman. Fecal Microbiota Transplantation. Patient Education Web Chapter. American College of Gastroenterology. 2016.. R Hsu, A. Yu, J. Lee, J Leung. Pancreatitis caused by common bile duct stones in a 3 year old boy with prior surgery for a choledochal cyst. Am J Gastro. 2001;96;6:1919-1921.. R Hsu, R Wolfgang. Which Drug Class is best for GERD? Patient Care. 2000 Sept;26-44.. RK Hsu, P Draganov, P Cotton, JW Leung, AS Yu, PR Tarnasky, JT Cunningham, RH Hawes. Therapeutic ERCP in the management of pancreatitis in children. Gastrointest Endosc. 2000;51:396-400.. J. Lee, R. Hsu, J Leung. Are self -expanding metal mesh stents useful in the treatment of benign esophageal stenosis and fistulas? An experience of four cases. Am J Gastro. 2000;95,8:1920-1925.. Lee JG, Turnispseed S, Romano PS, Vigil H, Hsu RK, Azari R, Kirk D, Melnikoff N, Sokolove P, Leung J. ...
ASM had organized lots of interesting presentations and the size of the venue was such that it took more than 15 minutes to walk from one side to the other side of the conference. Due to the time overlap of presentations and posters and the huge size of the venue, I was only able to attend a certain number of oral presentations. One of the best parts of the ASM conference was that I was able to see the trend of current research. To me, working on the human microbiome study, it was quite impressive because the number of talks and posters on human microbiome was significantly increased compared with my previous ASM meeting in San Francisco 2 years back. The microbiome studies was not limited to understanding microbial communities by 16S rRNA gene sequencing any more, but expanded their scope at the functional level with more mechanistical and practical approaches. One interesting session, for example, was on fecal microbiota transplantation. The talks were about successful trials on Clostridium ...
Larissa Rogge*, Ramona Calnan*, Rawnie Torres*, Matthew Spooner*, Andrew Brabban, and Elizabeth Kutter. (July 2008) Determining the Kinetics of a Therapeutic Phage Cocktail Targeting Pseudomonas aeruginosa, Edinburgh Phage Meeting, Scotland. M. Spooner*, L. Rogge*, B. Kutter and A. Brabban (Dec. 2007). Anaerobic Growth and Bacteriophage Infections of Pseudomonas aeruginosa, Phages in Interaction Symposium, Leuven, Belgium. Ramona Calnan*, Chris Judd*, Larissa Rogge*, Rawnie Torres*, Seamus Flynn*, Andrew Brabban and Elizabeth Kutter. (Dec. 2007) Determining the Properties of a Therapeutic Phage Cocktail, Phages in Interaction Symposium, Leuven, Belgium. C.M. Loc-Carrillo, A. Angermeyer*, M. Bennett*, M. Oetjens*, L. Gogokhia*, T. Kvelashvili, G. Bennett, Andrew Brabban, and Elizabeth Kutter. (2006) The Potential to Treat Chronic Dog-Ear Infections with Pseudomonas Specific Bacteriophages. ASM General Meeting. Orlando, Florida.. Rebecca Oot*, Raul Raya, Sarah Perigo*, Anna Castano*, Michael ...
A former R&D director of a private diagnostics company that focuses on bacterial tests, Drew Smith, has responded in online Q&As on why phage therapy has not taken off in most parts of the world. He listed lack of interest from pharma companies and financial backup as the top reasons for phage therapys absence in the modern western market. There is also the issue of regulation; regulating antibiotic use is easy because every pill of a given drug is chemically identical to the next. Phages, however, are dynamic entities whose populations will change (naturally or artificially) to target specific bacterial species. Current FDA-like regulations therefore make it difficult to manage so-called "dynamic" therapies, and the introduction of phage therapy to a western market would require novel policy considerations. But on a brighter note, almost two years ago the EU funded a clinical trial on phages to assess its international standards. The PhagoBurn project is the largest phage project today and ...
Phage therapy is a medical approach for the treatment of bacterial infectious diseases which makes use of the natural ability of some viruses, known as bacteriophages, to kill specific bacteria that they recognize. Phage therapy was first proposed nearly a century ago at the Institut Pasteur by the French-Canadian scientist Félix dHerelle. Although the technique was initially used worldwide, from the 1940s onwards it was particularly developed in Eastern Europe, while Western countries gradually lost interest in the approach and preferred to focus their attention on antibiotics, thought to be more promising. Medical use of phage therapy is currently hindered by the viral nature of this antibacterial treatment and the lack of precise knowledge about how bacteriophages work.. However, given the rise in bacterial resistance to antibiotics and the worrying prospect of a potential therapeutic impasse, scientists are once again beginning to explore the possibilities of bacteriophages. This field has ...
Biotherapy is defined as the use of living organisms in the treatment and diagnosis of human and animal diseases. This volume is an evocative exploration of the history, scientific basis and practical use of the major biotherapy modalities. The authors provide researchers and practitioners interested in this field, with cutting-edge material on the latest key advances in the following fields of biotherapy: Maggot Therapy, Hirudotherapy, Bee Venom Therapy, Apitherapy, Ichthyotherapy, Helminth Therapy, Phage Therapy, Animal Assisted Therapy, Canine Olfactory Detection. In addition, the authors provide with their chapters an extensive bibliography that represents a state-of-the-art survey of the literature. Comprehensive and current, this fresh volume of reviews is an essential resource for professionals who need to stay ahead of the game in the exciting field of biotherapy.
The use of biological therapy in patients suffering from rheumatoid arthritis and ankylosing spondylitis is getting more general. Basically with biologic therapy the action of a messenger of inflammation e.g. tumor necrosis factor (TNF) can be blocked - called anti-TNF therapy. The risk of this kind of impediment is becoming susceptible to infections or latent disease may turn into active and then may easier spread. The main danger is tuberculosis still other non-specific infections or malignant tumors may occur.. A retrospective study was made to analyze the data of patients treated with biological therapy and hospitalized in our institute because of severe pulmonary infections. The aim of this study was to detect the incidence and severity of these complications in a real life population.. Between 2008 and 2010 of 28705 patients with pulmonary disease were treated in our institute, 59 patients of them suffered rheumatic disease: 52 patients from rheumatoid arthritis and 7 of ankylosing ...
Menarini and Oxford BioTherapeutics are collaborating to develop antibody-based therapeutics for the treatment of cancer. The collaboration comprises five of
Eleven Biotherapeutics Inc (NASDAQ:EBIO) stock is at $0.578, up +1.58 percent from its previous close of $0.57. The stock opened the session at $0.67 and
Headlines about Iovance Biotherapeutics (NASDAQ:IOVA) have trended somewhat positive on Friday, Accern Sentiment reports. The research group scores the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being […]
BriefBrightPath Biotherapeutics Co Ltd formerly known as GreenPeptide Co Ltd is a biopharmaceutical venture company that develops novel cancer immunotherapies. The ...
Biotherapeutics | Scientific research info incl meetings, conferences, seminars, symposia,tradeshows,jobs,jobfairs, professional tips and more.
Shares of Iovance Biotherapeutics traded 12% higher after the firm reported updated clinical data from its phase 2 lifileucel metastatic melanoma trial.
DURHAM, N.C., Jan. 28, 2011 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SWX:OXBT) today announced it has signed a research contract with Hackensack University Medical Center (HUMC) to research wound healing properties of the Oxygen Biotherapeutics Wundecyte™ perfluorocarbon (PFC) and its novel oxygen-producing bandage for treatment of full-thickness excisional wounds and partial thickness burns. The preclinical study will also evaluate Wundecytes ability to prevent scar formation and improve infection control. This project will be funded by the U.S. Department of Defense.
Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Th
Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) was the target of a large drop in short interest during the month of December. As of December 15th, there was short interest totalling 2,514,282 shares, a drop of 61.1% from the November 30th total of 6,457,835 shares. Currently, 1.9% of the shares of the company are short sold. Based on […]
SIOUX FALLS, S.D.--(Business Wire/Korea Newswire) February 18, 2016 -- SAB Biotherapeutics, Inc. (SAB), a leading biopharmaceutical development company, announced today it has produced a new human antibody
CARMIEL, Israel, Feb. 5, 2013-- Protalix BioTherapeutics, Inc., confirms, in response to inquiries received this morning and a report appearing in the Israeli press, that the company has engaged Citigroup to assist it in reviewing a broad array of product partnering, technology sharing and other strategic alternatives.
吉林快三追号计划三期:Our biotherapeutics research products are designed for consistent and reproducible results, and are a component of GLP-compliant processes in the worlds leading pharmaceutical, biotechnology and CROs.
CARMIEL, Israel, April 2, 2013-- Protalix BioTherapeutics, Inc., announced today that the first patient has been treated in the Companys phase I clinical trial of PRX-112, or Oral GCD, the Companys orally-administered enzyme product candidate for the treatment of Gaucher disease.
This application note demonstrates how the addition of the ACQUITY QDa can improve the confidence and productivity when carrying out routine analysis of biotherapeutics.
Cambridge, MA-based Eleven Biotherapeutics said today that it has expanded its Series A financing by $20 million, bringing the total raised in the funding
Protalix BioTherapeutics, Inc. Due Diligence Report provides a complete overview of the companys affairs. All available data is presented in a comprehensive
... For the temporary relief of facial signs of fatigue due to: Stress, Unbalanced lifestyle, Pollution. Purchase Anti Age Skin/2 tubes online with free shipping!
From BioPortfolio: SummaryProtalix BioTherapeutics, Inc. Protalix is a biopharmaceutical company that develops and commercializes recombinant therapeutic proteins. The company
Conference Series LLC invites all the participants across the globe to attend the World Congress on Biotherapeutics slated on May 25-26, 2017 at Dallas, USA.
... For the temporary relief of wet and dry cough due to: Colds and flu, Bronchitis Chest congestion, Environmental irratitants, Smoking. Purchase Guna-Cough Syrup 150ml online with free shipping!
Company Name: NorthWest Biotherapeutics Inc., Stock Symbol: NWBO, Industry: Biotechs, Total Posts: 149681, Last Post: 12/16/2017 5:01:43 PM
CRISPR-focused Excision BioTherapeutics Strengthens Board of Directors Appointing Veteran Pharmaceutical Executive Bill Carson, M.D ...
AUSTIN, Texas, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to the discovery and develo...
Jan 18, 2008 - GTC Biotherapeutics, Inc. ( GTC , Nasdaq GTCB) announced today that on January 17, 2008 it received notice from The Nasdaq Stock Market that for
Get detailed financial information on Iovance Biotherapeutics Inc (NASDAQ:IOVA) including real-time stock quotes, historical charts & financial news, all for free!
Northwest Biotherapeuticss number of active job openings can be viewed here. Find out what Northwest Biotherapeutics is hiring for.
Phage therapy is the use of bacterial viruses (phages) to treat bacterial infections, a medical intervention long abandoned in the West but now experiencing a revival. Currently, therapeutic phages are often chosen based on limited criteria, sometimes merely an ability to plate on the pathogenic bacterium. Better treatment might result from an informed choice of phages. Here we consider whether phages used to treat the bacterial infection in a patient may specifically evolve to improve treatment on that patient or benefit subsequent patients. With mathematical and computational models, we explore in vivo evolution for four phage properties expected to influence therapeutic success: generalized phage growth, phage decay rate, excreted enzymes to degrade protective bacterial layers, and growth on resistant bacteria. Within-host phage evolution is strongly aligned with treatment success for phage decay rate but only partially aligned for phage growth rate and growth on resistant bacteria. Excreted enzymes
News Release by Takeda Canada.. OAKVILLE, Ontario - May 19, 2015 - ENTYVIO™ (vedolizumab), a new biologic treatment to treat ulcerative colitis (UC), one of the two most common types of inflammatory bowel disease, is now available in Canada.. UC is a condition that can be very debilitating and significantly compromise quality of life for the patient and affects more than 125,000 Canadians. Additionally, inflammatory bowel disease has been labelled Canadas "national disease" due to Canada having among the highest rates in the world.. ENTYVIO™ is the first and only gut-selective biologic therapy with no known systemic immunosuppressive effects and the only biologic treatment approved for use in UC patients who have had an inadequate response, loss of response or were intolerant to infliximab, a TNFα antagonist. ENTYVIO™ works by targeting the gut, directly reaching inflammation that causes symptoms of UC. In clinical studies, ENTYVIO™ demonstrated statistically significant benefits ...
In the IMAgINE 1 study, which evaluated the safety and efficacy of ADA double-blind maintenance dosing regimens following open-label induction for paediatric patients with moderate to severe CD, haematologic AEs were mostly anaemia - 22 out of 39 events [24]. The results of our analysis are consistent with those of Hyams et al., since anaemia was not only the most common haematological AE but also the most frequently reported AE generally. However, most patients presented with anaemia or other haematologic AEs such as leucopaenia also had concomitant treatment with either IMM or corticosteroid. Therefore, it is possible that their occurrence was associated with the use of concomitant medication rather than with the biologic agent. Besides, one third of IBD patients suffer from recurrent iron deficiency anaemia [25], which may explain the fact that this haematological disorder was the most common AE reported in our analysis. It is even more plausible because 4 out of 17 patients (23.5%) ...
Northwest Biotherapeutics, Inc. , Northwest Biotherapeutics ( NWBT ) announced today that Lonza Group AG has withdrawn all claims of patent infringement involvi
Disclosure: E. H. Choy, Abbott Laboratories, Amgen, Boehringer Ingelheim, Chelsea Therapeutics, Chugai Pharma, Ferring Pharmaceuticals, GSK, Jazz Pharmaceuticals, Janssen, MSD, Novartis, Pierre Fabre Medicament, Novimmune, Roche, UCB, 2,Abbott Laboratories, Allergan, Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Chelsea Therapeutics, Chugai Pharma, Daiichi Sankyo, Eli Lilly, Ferring Pharmaceutical, GSK, Hospita, ISIS, Jazz Pharmaceuticals, Janssen, MedImmune, Merrimack Pharmaceutical, M, 5,Abbott Laboratories, Amgen, Boehringer Ingelheim, Chugai Pharma, Eli Lilly, Jazz Pharmaceuticals, MSD, Novartis, Pfizer, Pierre Fabre Medicament, Regeneron, Roche, Schering Plough, Synovate, UCB, 8; C. Bernasconi, Roche, 5; M. Aassi, F. Hoffmann-La Roche, 3; J. F. Molina, Amgen, Janssen, MSD, Novartis, Pfizer, Roche, 2,Eli Lilly, GSK, MSD, Pfizer, 5,Eli Lilly, GSK, MSD, Pfizer, 8; O. M. Epis, Abbott Laboratories, Pfizer, Roche, Laborest, Sanofi, Fidia farmaceuti, BMS, 8 ...
Expert Opinion on Biological Therapy. 8 (12): 1955-62. doi:10.1517/14728220802517901. PMID 18990082.. ... "The Journal of Biological Chemistry. 265 (26): 15361-4. PMID 2394726.. *^ Padayatty SJ, Katz A, Wang Y, Eck P, Kwon O, Lee JH, ... "The Journal of Biological Chemistry. 269 (13): 9397-400. PMID 8144521.. *^ Wells WW, Xu DP, Yang YF, Rocque PA (September 1990 ... "The Journal of Biological Chemistry. 263 (33): 17205-8. PMID 3053703.. *^ Gaballa A, Newton GL, Antelmann H, Parsonage D, Upton ...
Hall, R. A.; Khromykh, A. A. (2004). "West Nile virus vaccines". Expert Opinion on Biological Therapy. 4 (8): 1295-1305. doi: ... Titball, R. W.; Williamson, E. D. (2004). "Yersinia pestis (plague) vaccines". Expert Opinion on Biological Therapy. 4 (6): 965 ... Expert Opinion on Biological Therapy. 10 (2): 179-190. doi:10.1517/14712590903379502. PMID 20088713.. ... A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent ...
Expert Opinion on Biological Therapy. 12 (4): 395-410. doi:10.1517/14712598.2012.664129. PMID 22335323.. ... "International Journal of Biological Sciences. 6 (7): 834-844. doi:10.7150/ijbs.6.834. PMC 3005349. PMID 21179590.. ... "Discourses: Biological & Geological (volume VIII) : Yeast". Collected Essays. Retrieved 28 November 2009 ...
Eckstein, Fritz (2007). "The versatility of oligonucleotides as potential therapeutics". Expert Opinion on Biological Therapy. ... "Journal of Biological Physics. 33 (5-6): 345-356. doi:10.1007/s10867-008-9074-3. PMC 2565759. PMID 19669523.. ... "Molecular Therapy. 17 (1): 95-103. doi:10.1038/mt.2008.215. PMC 2834975. PMID 18957965.. ... A reevaluation of the mechanism of cellular uptake". The Journal of Biological Chemistry. 278 (1): 585-90. doi:10.1074/jbc. ...
Expert Opinion on Biological Therapy. 7 (5): 599-615. doi:10.1517/14712598.7.5.599. PMID 17477799.. ... Anticancer therapy[edit]. Since NK cells recognize target cells when they express nonself HLA antigens (but not self), ... Smyth MJ, Hayakawa Y, Takeda K, Yagita H (November 2002). "New aspects of natural-killer-cell surveillance and therapy of ... respond better to antibody therapy. This has been shown for lymphoma patients who received the antibody Rituxan. Patients who ...
Expert Opinion on Biological Therapy. 13 (11): 1613-21. doi:10.1517/14712598.2013.840285. PMID 24088009.. ... Proceedings of the Royal Society B: Biological Sciences. 278 (1702): 42-49. doi:10.1098/rspb.2010.1107. PMC 2992723. PMID ...
Lima, X. T.; Abuabara, K.; Kimball, A. B.; Lima, H. C. (2009). "Briakinumab". Expert Opinion on Biological Therapy. 9 (8): 1107 ...
Expert opinion on biological therapy. 10 (7): 1077-87. PMID 20455790. doi:10.1517/14712598.2010.487060.. ...
Expert Opinion on Biological Therapy. 18 (4): 369-379. doi:10.1080/14712598.2018.1421169. PMID 29285958.. ... A biopharmaceutical, also known as a biologic(al) medical product, biological,[1] or biologic, is any pharmaceutical drug ... Gene therapy[edit]. Viral gene therapy involves artificially manipulating a virus to include a desirable piece of genetic ... Some regulatory agencies use the terms biological medicinal products or therapeutic biological product to refer specifically to ...
Expert Opinion on Biological Therapy. 15 (8): 1183-90. doi:10.1517/14712598.2015.1049943. PMID 26160491.. ... The authors stated "…the use of HCG should be regarded as an inappropriate therapy for weight reduction…" In the authors ... As the most abundant biological source is women who are presently pregnant, some organizations collect urine from pregnant ... Restraints on physicians practicing this therapy can be based on our findings." ...
Graham, Lloyd D (2002). "Ecdysone-controlled expression of transgenes". Expert Opinion on Biological Therapy. 2 (5): 525-35. ... Although mammals lack this receptor, 20-hydroxyecdysone may affect mammalian (including human) biological systems in vitro, but ... For uses in gene therapy, it may be necessary to investigate more thoroughly the natural sources of ecdysteroids in humans ( ... This would explain the mechanism behind Helminthic therapy due to the production of ecdysteroids by helminths, as mentioned ...
Expert Opinion on Biological Therapy. 18 (4): 369-379. doi:10.1080/14712598.2018.1421169. PMID 29285958.. ... Gene therapy[edit]. Viral gene therapy involves artificially manipulating a virus to include a desirable piece of genetic ... Some regulatory agencies use the terms biological medicinal products or therapeutic biological product to refer specifically to ... European Medicines Agency, "tooltip definition of advanced therapy medicinal products", Committee for Advanced Therapies (CAT) ...
Biological therapy for inflammatory bowel disease. References[edit]. *^ a b c d "Infliximab, Infliximab-dyyb Monograph for ... Maintenance therapy with the drug (versus intermittent or sporadic therapy) lessens the likelihood of developing antibodies to ... "Promising biological therapies for ulcerative colitis: A review of the literature". World Journal of Gastrointestinal ... Infliximab neutralizes the biological activity of TNF-α by binding with high affinity to the soluble (free floating in the ...
Biological therapyEdit. Selection of biological targets on the basis of their combinatorial effects on the leukemic ... Radiation therapyEdit. Radiation therapy (or radiotherapy) is used on painful bony areas, in high disease burdens, or as part ... Chemotherapy, stem cell transplantation, radiation therapy, targeted therapy[1]. Prognosis. Children: 90% five-year survival ... "Press Announcements-FDA approval brings first gene therapy to the United States". www.fda.gov. Archived from the original on 3 ...
"Erythroderma in the era of biological therapies". Eur J Dermatol. 22 (2): 167-71. doi:10.1684/ejd.2011.1569. PMID 22321651. ...
Cheng JH, Wang CJ (2015). "Biological mechanism of shockwave in bone". International Journal of Surgery. 24: 143-6. doi:10.1016 ... Extracorporeal shockwave therapy (ESWT) is a treatment mostly used to treat kidney stones and in physical therapy and ... Extracorporeal shockwave therapy is used as a second line measure to treat tennis elbow,[9][10] shoulder rotator cuff pain,[11] ... Yin MC, Ye J, Yao M, Cui XJ, Xia Y, Shen QX, Tong ZY, Wu XQ, Ma JM, Mo W (2014). "Is extracorporeal shock wave therapy clinical ...
Cunningham, AL (2016). "The herpes zoster subunit vaccine". Expert opinion on biological therapy. 16 (2): 265-71. doi:10.1517/ ... Furuta Y, Ohtani F, Mesuda Y, Fukuda S, Inuyama Y (2000). "Early diagnosis of zoster sine herpete and antiviral therapy for the ... immunosuppressive therapy, psychological stress, or other factors.[38][39] Upon reactivation, the virus replicates in neuronal ... and as therapy during the acute phase. Complications in immunocompromised individuals with shingles may be reduced with ...
"Xolair - Biological Therapy". Drugdevelopment-technology.com. Leung DY, Sampson HA, Yunginger JW, et al. (2003). "Effect of ... Chang is a cofounder of Tanox, a biopharmaceutical company specialized in anti-IgE therapies for the treatment of allergic ... Chang TW, 2000, "The pharmacological basis of anti-IgE therapy." Nature Biotechnology, 18(2), 157-162. Chang TW and Shiung YY, ... anti-IgE therapy in patients with peanut allergy". N. Engl. J. Med. 348 (11): 986-93. doi:10.1056/NEJMoa022613. PMID 12637608. ...
"Stem cell-based biological tooth repair and regeneration". Trends in Cell Biology. 20 (12): 715-22. doi:10.1016/j.tcb.2010.09. ... Bone marrow transplant is the most widely used stem-cell therapy, but some therapies derived from umbilical cord blood are also ... a b c d Kane, Ed (May 2008). Stem-cell therapy shows promise for soft-tissue injury, disease. DVM Newsmagazine. 6E-10E. ... Stem-cell therapy is the use of stem cells to treat or prevent a disease or condition.[1] ...
"Expert Opinion on Biological Therapy. 8 (2): 181-90. doi:10.1517/14712598.8.2.181. PMC 2789278. PMID 18194074.. ... Studies of correcting Wiskott-Aldrich syndrome with gene therapy using a lentivirus have begun.[15][16] Proof-of-principle for ... Malech HL, Ochs HD (April 2015). "An emerging era of clinical benefit from gene therapy". JAMA. 313 (15): 1522-3. doi:10.1001/ ... Gallagher, James (21 April 2015) Gene therapy: 'Tame HIV' used to cure disease BBC News, Health, Retrieved 21 April 2015 ...
Expert Opinion on Biological Therapy. 8 (12): 1955-62. doi:10.1517/14728220802517901. PMID 18990082.. ... Mucolytic therapyEdit. Inhaled acetylcysteine has been used for mucolytic ("mucus-dissolving") therapy in addition to other ... "Biological Psychiatry. 71 (11): 978-86. doi:10.1016/j.biopsych.2011.10.024. PMC 3340445 . PMID 22137594.. ... Samuni Y, Goldstein S, Dean OM, Berk M (Aug 2013). "The chemistry and biological activities of N-acetylcysteine". Biochimica et ...
"Biological therapy for kidney cancer". 2017-08-30.. *^ Jonasch, Eric; Messner, Carolyn (August 2012). "CancerCare Connect - ... Surgery, radiation therapy, chemotherapy, immunotherapy, targeted therapy[1][2][3]. Prognosis. Five-year survival ~75% (US 2015 ... Other treatment options include biological therapies such as everolimus, torisel, nexavar, sutent, and axitinib, the use of ... Treatment may include surgery, radiation therapy, chemotherapy, immunotherapy, and targeted therapy.[1][2][3] Kidney cancer ...
Taylor, Robert W (2005). "Gene therapy for the treatment of mitochondrial DNA disorders". Expert Opinion on Biological Therapy ... Presently, gene therapy and nutraceutical supplementation are popular areas of ongoing research. Bjelakovic et al. analyzed the ... An IVF technique known as mitochondrial donation or mitochondrial replacement therapy (MRT) results in offspring containing ... Journal of Biological Chemistry. 281 (1): 374-82. doi:10.1074/jbc.M509730200. PMID 16263719. Jemt, E.; Farge, G.; Backstrom, S ...
Other treatment options include biological therapies such as everolimus, torisel, nexavar, sutent, and axitinib, the use of ... "Biological therapy for kidney cancer". Jonasch, Eric; Messner, Carolyn (August 2012). "CancerCare Connect - Treatment Update: ... There is currently no evidence that body-wide medical therapy after surgery where there is no known residual disease, that is, ... adjuvant therapy, helps to improve survival in kidney cancer. If the cancer cannot be treated with surgery other techniques ...
Expert opinion on biological therapy. 9 (5): 649-57. doi:10.1517/14712590902926071. PMID 19392579. Schubert-Zsilavecz, M, ...
"β-Catenin". Sino Biological Inc.: Biological Solution Specialist. Reynolds AB (June 2011). "Epithelial organization: new ... Recently, there have been a number of studies in the lab and in the clinic investigating new possible therapies for cancers ... Coluzzi F, Mandatori I, Mattia C (September 2011). "Emerging therapies in metastatic bone pain". Expert Opin Emerg Drugs. 16 (3 ...
WebMD looks at a treatment for breast cancer known as targeted therapy. It uses the bodys own immune system to act on cancer ... Targeted therapy, also called biologic therapy, uses the bodys immune system or hormonal system to fight breast cancer cells. ... Targeted Therapy for Breast Cancer. Articles OnBreast Cancer Treatment Options. Breast Cancer Treatment Options Breast Cancer ... One type of targeted therapy uses antibodies to kill cancer cells or block them from growing. Antibodies are a part of the ...
Targeted Radionuclide Tumor Therapy: Biological Aspects. Torgny Stigbrand,Jorgen Carlsson,Gregory P. Adams. No preview ... Targeted Radionuclide Tumor Therapy: Biological Aspects. Torgny Stigbrand,Jorgen Carlsson,Gregory P. Adams. No preview ... The title of this book "Targeted Radionuclide Tumour Therapy - Biological Aspects" was selected to reinforce the concept that a ... activation Affibody molecule affinity antigen apoptosis apoptotic Auger electrons binding biodistribution Biol biological ...
... such as gene therapy and cancer vaccines, to harness the bodys immune system to fight cancer. ... Targeted drug therapy. Many types of biological therapy are available only in clinical trials. Biological therapy for cancer is ... How biological therapy works. The goal of biological therapy for cancer is to induce your immune system to recognize and kill ... biological therapies work by:. *Inducing the immune system to attack cancer cells. There are several ways biological therapy ...
Biological therapies for cancer. National Cancer Institute. http://www.cancer.gov/cancertopics/factsheet/Therapy/biological. ...
Biological reprogramming in acquired resistance to endocrine therapy of breast cancer. H Aguilar1, X Solé2,3, N Bonifaci2,3, J ... Ghayad et al., 2009). Notably, ERBB2 amplification was associated with resistance to endocrine therapies (. Ellis et al., 2006 ... Endocrine therapies are the most effective systemic treatment of estrogen receptor α (ERα)-positive breast cancer, and over two ... Winer et al., 2002). Two major strategies mediate the efficacy of these therapies. Drugs directed at ERα, mainly tamoxifen and ...
Biological therapy may be used to treat chronic myelogenous leukemia in the chronic or accelerated phase. Learn about ... Biological therapy drug used for CML. Interferon alfa (Intron A, Wellferon) is the biological therapy occasionally used to ... Biological therapy is also called biotherapy or biological response modifiers (BRMs).. In most cases, targeted therapies are ... Biological therapy for chronic myelogenous leukemia. Biological therapy is sometimes used to treat chronic myelogenous leukemia ...
... biological response modifiers and the family of cell adhesion-promoting molecules. ... Biological Treatments in Behçets Disease: Beyond Anti-TNF Therapy. Francesco Caso,1,2 Luisa Costa,3 Donato Rigante,4 Orso ... We found 44 cases of BD patients in therapy with biological agents other than anti-TNF-α agents. In particular, we found eight ... corticosteroid therapy is recommended for dural sinus thrombosis, while a combination therapy of corticosteroids with ...
Learn how and when biological therapy is used and side effects of biological therapy. ... Biological therapy is used treat certain types of non-Hodgkin lymphoma. ... Biological therapy is also called biotherapy or biological response modifiers (BRMs).. You may have biological therapy to:* ... Biological therapy for non-Hodgkin lymphoma. Biological therapy is sometimes used to treat non-Hodgkin lymphoma (NHL). It uses ...
Is it safe to use biologic therapies for psoriasis in women of child-bearing age? This systemic review found that the safety of ... Exposure to Biological Therapies During Conception and Pregnancy. A Systematic Review. E. Pottinger; R.T. Woolf; L.S. Exton; A. ... The aim of the review was to investigate outcomes in women exposed to biological therapies relevant to the treatment of ... has received departmental funding for research from pharmaceutical companies involved in manufacturing biological therapies ...
Is it safe to use biologic therapies for psoriasis in women of child-bearing age? This systemic review found that the safety of ... Exposure to Biological Therapies During Conception and Pregnancy. A Systematic Review. E. Pottinger; R.T. Woolf; L.S. Exton; A. ... Background Biological therapies are effective treatments for psoriasis and are often prescribed to women of child-bearing age. ... All of the biological therapies currently licensed for psoriasis are derivatives of human immunoglobulin G (IgG) and are ...
... or biological therapy, uses the bodys immune system to fight cancer and other diseases. Learn more about immunotherapy ... Immunotherapy, also known as biological therapy or biotherapy, uses the bodys immune system to fight diseases such as cancer. ... What Is Hormonal Therapy for Breast Cancer? A hormone receptor positive tumor means that the breast cancer cells have a ...
Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy.. Miller WR1, Dixon JM, Cameron DA, Anderson TJ. ... there was a decrease with therapy in immunohistochemical staining for Ki67 in all tumours. Staining for progesterone receptor ( ...
Biological therapy downregulates the heterodimer S100A8/A9 (calprotectin) expression in psoriatic patients. ... the expression of the heterocomplex S100A8/A9 in lesional skin from psoriatic patients undergoing biological therapy with ... Balato A, Schiattarella M, Di Caprio R, Lembo S, Mattii M, Balato N, Ayala F. Effects of adalimumab therapy in adult subjects ... Furthermore, we have shown that the biological treatment induced a drastic reduction of S100A8/A9 expression in skin biopsies ...
The light ions have a unique role in the development of modern radiation therapy where biological optimized radiation quality ... and intensity-modulated radiation therapy are increasingly coming into... ... The light ions have a unique role in the development of modern radiation therapy where biological optimized radiation quality ... Brahme A. (2011) Physical, Biological and Clinical Background for the Development of Light Ion Therapy. In: Levitt S., Purdy J ...
Targeted (biological) therapies information for you Related. Order booklets or audio CDs about targeted (biological) therapies ... biological or hormonal therapies, transplants, and clinical trials.. Latest posts in Cancer treatments. Jenny62 replied to jane ...
... sometimes known as biological therapies) can be used to stimulate the immune system, control the growth of cancer cells or to ... Targeted (biological) therapies information for you Related. Order booklets or audio CDs about targeted (biological) therapies ... Back to Targeted therapy explained. Targeted (biological) therapy for cancer of the larynx. A targeted therapy drug called ... Targeted therapies (sometimes known as biological therapies) can be used to stimulate the immune system, control the growth of ...
CRISPR-Responsive Materials Deliver Therapy on Biological Cues. August 29th, 2019 Medgadget Editors Genetics, Materials, ... giving smart biological functionality to whatever material it is in. ... deliver therapies, and do things that are currently impossible. ... Nanoparticles for Large Gene Therapy to Cure Common Eye ...
... By Jonathan Lotempio, Jr.. Scientific Program Analyst, NHGRI. Ludwig ... While gene therapy with AAV2/1-Cba-Tmc1 would likely not have helped Beethoven, since scholars can be nearly certain that he ... Gene therapy, however, may answer that technologic need. Adeno-associated viruses (AAV) have long been a promising vector for ... Tmc gene therapy restores auditory function in deaf mice. Sci Transl Med, 7(295):295ra108. 2015. [PubMed] ...
Targeted (biological) therapies information for you Related. Order booklets or audio CDs about targeted (biological) therapies ... Find your targeted (biological) therapy. Find more information about the therapy youre having. ... Targeted (biological) therapies for Hodgkin lymphoma. This treatment is sometimes used for Hodgkin lymphoma that has come back ... biological or hormonal therapies, transplants, and clinical trials.. Latest posts in Cancer treatments. Gordon.b replied to ...
You might be given a type of biological therapy called a monoclonal antibody. This can damage the harmful cells in lymphoma. ... Targeted (biological) therapies You might be given a type of biological therapy called a monoclonal antibody. This can damage ... Targeted (biological) therapies information for you Related. Order booklets or audio CDs about targeted (biological) therapies ... Targeted and biological therapies explained. Targeted and biological therapies can change cells to treat cancer. ...
... is also known as immunotherapy and works with the bodys natural ability to control ... Immune therapies may repair, stimulate or enhance the bodys immune response. Biological therapies include monoclonal ... This therapy is targeted to protect the body from side effects of cancer treatment. ...
Download all the latest market reports you need on the Biological Therapy Industry in India. Click here to instantly access all ... Biological Therapy Industry in India Market Research & Statistics. Biological Therapy Industry in India Market Research & ...
Download all the latest market reports you need on the Biological Therapy Industry in Europe. Click here to instantly access ... Global Stem Cell Therapy Market Analysis & Trends - Ind ... $ 4200 November 2017 The Global Stem Cell Therapy Market is poised ... Biological Therapy Industry in Europe Market Research & Statistics. Biological Therapy Industry in Europe Market Research & ...
Biological proteins have unlimited potential for use as pharmaceutical products due to their various biological activities, ... allow for the development of novel innovative protein-based products that draw on the quality of their innate biological ... review attempts to provide an overview of the development of protein-based products that take advantage of their biological ... Potential Use of Biological Proteins for Liver Failure Therapy. Kazuaki Taguchi 1. ...
What are targeted (biological) therapies? Targeted therapies are sometimes known as biological therapies. They interfere with ... Targeted (biological) therapies information for you Related. Order booklets or audio CDs about targeted (biological) therapies ... How targeted therapies work. How targeted therapies work. This animation shows how targeted therapies work and what effect they ... biological or hormonal therapies, transplants, and clinical trials.. Latest posts in Cancer treatments. canterbury replied to ...
  • In early 2016, Sierra Sciences announced that they were working with BioViva to start a new medical tourism-based venture, BioViva FIJI, on Fiji and that they will be the first company to use gene therapy to treat biological aging in humans. (wikipedia.org)
  • BioViva released data gathered post-therapy in 2016, claiming that independent testing by SpectraCell Laboratories had revealed Parrish's leukocyte telomere length had been extended from 6.71kb to 7.33kb, an amount they state is equivalent to a reversal of 20 years of telomere attrition. (wikipedia.org)
  • Therefore, additional therapies for a subset of refractory patients with BD are inevitably needed. (hindawi.com)
  • The aim of this study was to investigate, by immunohistochemical analysis, the expression of the heterocomplex S100A8/A9 in lesional skin from psoriatic patients undergoing biological therapy with adalimumab, etanercept or ustekinumab. (springer.com)
  • July's Genome Advance of the Month highlights a study in the journal Science Translational Medicine that demonstrated gene therapy as an effective way to improve hearing in patients with two genes linked to genetic prelingual deafness, or hearing loss that occurs before a child learns to speak. (genome.gov)
  • PURPOSE: Phase II trial to compare the effectiveness of indomethacin and biological therapy with or without cyclophosphamide in treating patients who have advanced melanoma that has not responded to previous therapy. (clinicaltrials.gov)
  • V. Generate and use lymphokine-activated killer (LAK) cells in those patients who do not have TIL available for therapy and evaluate LAK cells in the same manner as TIL. (clinicaltrials.gov)
  • They also are produced in the laboratory and given to cancer patients in biological therapy. (vcu.edu)
  • Stage IV GC patients can be divided based on the absence (categories 1 and 2) or presence (categories 3 and 4) of macroscopically detectable peritoneal dissemination, which has a different biological outcome compared to hematological metastasis. (springer.com)
  • The indications for conversion therapy might include the patients from category 2, some patients from category 3 and a very small number of patients from category 4. (springer.com)
  • The provision of conversion therapy for stage IV GC patients might be one of the main roles of surgical oncologists in the near future. (springer.com)
  • OUTLINE: Patients receive cytoreductive tumor surgery and/or biopsy and implantation of intracavitary Ommaya reservoir prior to therapy induction. (knowcancer.com)
  • The use of biological therapy in patients suffering from rheumatoid arthritis and ankylosing spondylitis is getting more general. (ersjournals.com)
  • A retrospective study was made to analyze the data of patients treated with biological therapy and hospitalized in our institute because of severe pulmonary infections. (ersjournals.com)
  • 27 of 59 patients received some sort of non-biological therapy, 23 of 59 got no medication and we screened 3 patients before the biological therapy. (ersjournals.com)
  • Six of the 9 patients who received biological therapy had complications: 5 cases of tuberculosis, 1 case of pulmonary abscess, 1 case of invasive aspergillosis. (ersjournals.com)
  • Conclusions In PsA patients, the initial presence of enthesitis is an independent risk factor associated with the need for biological therapy during the follow-up. (bmj.com)
  • The purpose of this phase I/II trial is to study the side effects and best dose of biological therapy to treat patients at high-risk or with Epstein-Barr virus-associated lymphoma or lymphoproliferative disease. (clinicaltrials.gov)
  • This phase I/II trial is studying the side effects of biological therapy and to see how well it works in treating patients with advanced myelodysplastic syndrome, chronic myeloid leukemia, acute myeloid leukemia, or acute lymphoblastic leukemia. (clinicaltrials.gov)
  • Following chemobiotherapy, maintenance therapy is administered to patients with stable or responding disease. (clinicaltrials.gov)
  • Patients who required immunosapressant and biological agents were 24 patients (10%) out of 227 patients with scleritis. (arvojournals.org)
  • Extraglandular involvement requires organ-specific therapy generally based upon some combination of glucocorticoids and immunosuppressive agents, similar to that applied in patients with systemic lupus erythematosus (SLE) . (springer.com)
  • Gamida Cell's flagship product, StemEx, is now being studied as a therapy for patients with blood cancers in an international pivotal trial at leading transplant centers in the U.S., Europe and Israel. (marketwired.com)
  • OUTLINE: Patients are stratified according to extent of disease, extent of antigen specific response to vaccination, performance status (0 vs 1), prior therapy (yes vs no), and gender. (knowcancer.com)
  • Advances in cognitive behavioral therapy methods, such as Exposure therapy have improved our ability to treat patients with these conditions. (wikipedia.org)
  • IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma. (wikipedia.org)
  • A large, 296-patient, Phase III clinical trial called the ACCENT 2 trial, showed infliximab was additionally beneficial in maintaining closure of fistulae, with almost two-thirds of all patients treated with the three initial doses of infliximab having a fistula response after 14 weeks, and 36% of patients maintaining closure of fistulae after a year, compared with 19% who received placebo therapy. (wikipedia.org)
  • Patients tolerate the therapy safely but, as in any therapy, there are adverse effects and care should be taken in its application, particularly to children. (wikipedia.org)
  • Another government scheme hopes to increase the number of new diagnostics and therapies for patients, while reducing the time and cost of developing these. (wikipedia.org)
  • Cold viruses generally get a bad rap----which they've certainly earned----but new findings by a team of scientists at the Salk Institute for Biological Studies suggest that these viruses might also be a valuable ally in the fight against cancer. (biospace.com)
  • Matherials and Methods We identified 9 children with JIA treated with biologic therapies, and we made a description of our experience. (bmj.com)
  • However, the advent of biologic therapeutics has also raised complex regulatory issues (see below), and significant pharmacoeconomic concerns, because the cost for biologic therapies has been dramatically higher than for conventional (pharmacological) medications. (wikipedia.org)
  • The effectiveness of light therapy for treating SAD may be linked to the fact that light therapy makes up for lost sunlight exposure and resets the body's internal clock. (wikipedia.org)
  • Data generated from both clinical trials and model systems indicate that both types of therapy may prevent the progression of pump dysfunction that characterizes the natural history of heart failure and, unexpectedly and remarkably, that β-blockade may substantially improve pump function in the long term. (ahajournals.org)
  • The report covers biological products in development, biological products in clinical trials, and currently marketed and late-stage development biologic cancer products. (bccresearch.com)
  • Noncytotoxic maneuvers that short circuit damage resistance loops may thus represent an indirect form of gene therapy meriting incorporation into hepatocellular carcinoma clinical trials. (aacrjournals.org)
  • Oncolytics Biotech Inc. has collaborated with the National Cancer Institute (NCI), the University of Leeds, the Canadian Cancer Trials Group (CCTG) (formerly the National Cancer Institute of Canada Clinical Trials Group) and the Cancer Therapy & Research Centre at the University of Texas Health Science Center in San Antonio, among others, to conduct multiple clinical trials in the United States and United Kingdom. (wikipedia.org)
  • However, even though there is extensive experience in the clinical use of protons, there remains much to be learned regarding the relative biological effectiveness (RBE) of protons in relation to photons. (bl.uk)
  • Typically the evaluation of relative biological effectiveness is done on various types of living cells grown in culture medium, including prokaryotic cells such as bacteria, simple eukaryotic cells such as single celled plants, and advanced eukaryotic cells derived from organisms such as rats. (wikipedia.org)
  • The primary advantage of alpha particle (α) emitters over other types of radioactive sources is their very high linear energy transfer (LET) and relative biological effectiveness (RBE). (wikipedia.org)
  • Her primary focus areas include oncology and cardiovascular diseases, along with expertise in molecular and cell biology and complex cell-based biological assays, ranging from drug discovery, in vitro and in vivo screening, in vivo model development and pharmacokinetics. (bccresearch.com)
  • We describe the protocols used to investigate the interactions of 13.56 MHz radiofrequency (RF) electric-fields with gold nanoparticle colloids in both non-biological and biological systems ( in vitro / vivo ). (jove.com)
  • Although mammals lack this receptor, 20-hydroxyecdysone may affect mammalian (including human) biological systems in vitro, but there is uncertainty whether any in vivo or physiological effects occur. (wikipedia.org)
  • Parthenolide has a variety of reported in vitro biological activities, including: Inhibition HDAC1 protein without affecting other class I/II HDACs, which leads to sustained DNA damage response in certain cells (required for apoptosis). (wikipedia.org)
  • Autologous immune enhancement therapy use a person's own peripheral blood-derived natural killer cells, cytotoxic T lymphocytes and other relevant immune cells are expanded in vitro and then reinfused. (wikipedia.org)
  • Background Biological therapies have dramatically changed the prognosis for children with juvenile idiopathic arthritis (JIA). (bmj.com)
  • Background- Biological pacing performed solely via HCN2 gene transfer in vivo results in relatively slow idioventricular rates and only moderate autonomic responsiveness. (ahajournals.org)
  • The remaining challenge to a more wide spread clinical use of light ions are to improve the sensitivity and specificity of Molecular Tumor Imaging to more accurately localize the tumor tissues and their biological characteristics as well as to develop fast scanning systems that preserve the fundamental biological and physical advantages of the light ions. (springer.com)
  • However, most breast tumors initially responsive to these therapies develop resistance through molecular mechanisms that are not yet fully understood. (nature.com)
  • those with unresectable tumors or insufficient TIL are treated on Regimen B. The following acronyms are used: CTX Cyclophosphamide, NSC-26271 IL-2 Interleukin-2 (Cetus), NSC-373364 LAK Lymphokine-Activated Killer Cells TIL Tumor Infiltrating Lymphocytes Regimen A: Prostaglandin Inhibition Therapy plus Biological Response Modifier Therapy. (clinicaltrials.gov)
  • DEDIĆ PLAVETIĆ NDP, BARIĆ MB, BRADIĆ LB, KULIĆ A, PLEŠTINA S. Hypoxia in solid tumors: biological responses to hypoxia and implications on therapy and prognosis. (srce.hr)
  • N.D.P. DEDIĆ PLAVETIĆ, M.B. BARIĆ, L.B. BRADIĆ, A. KULIĆ i S. PLEŠTINA, "Hypoxia in solid tumors: biological responses to hypoxia and implications on therapy and prognosis", Periodicum biologorum , vol.116, br. (srce.hr)
  • Another type of this therapy uses drugs made of small molecules that block signals the cancer cells need to grow. (webmd.com)
  • Your healthcare team will consider your personal needs to plan the drugs, doses and schedules of biological therapy. (cancer.ca)
  • The following biological therapy drugs may be used to treat certain types of NHL. (cancer.ca)
  • Epigenetic therapy is the use of drugs or other epigenome-influencing techniques to treat medical conditions. (wikipedia.org)
  • On a clinical level, it includes various therapies, such as drugs, diet, avoidance of environmental contaminants, exercise, and alleviation of the adverse effects of life stress, all of which can cause measurable biochemical changes. (wikipedia.org)
  • It is thus vital to pinpoint the right biological targets (genes, proteins and other molecules) early in the process, so as to design more rational drugs and better tailored therapies. (wikipedia.org)
  • It was largely because positive inotropic or vasodilator agents can acutely shift the cardiac output/preload relation upward and to the left that these types of pharmacological therapies constituted the initial attempts to improve the natural history of chronic heart failure. (ahajournals.org)
  • It has also been speculated that some of the metabolites of CBD have pharmacological effects that contribute to the biological activity of CBD. (wikipedia.org)
  • Aguilar-Company J, Fernández-Ruiz M, García-Campelo R, Garrido-Castro AC, Ruiz-Camps I. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Cell surface receptors and associated signaling pathways). (harvard.edu)
  • Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases. (harvard.edu)
  • Despite the possible occurrence of severe complications this therapy has got major efficiency in treating rheumatic diseases. (ersjournals.com)
  • The areas covered include basic and clinical research, including studies in cardiovascular medicine, endocrinology, neurological diseases, oncology, wherever guided-therapy with biological markers is used. (m-hikari.com)
  • For uses in gene therapy, it may be necessary to investigate more thoroughly the natural sources of ecdysteroids in humans (which appear to include dietary phytoecdysteroids, gut flora, helminth infections, and other diseases). (wikipedia.org)
  • Brahme A (2011) Accurate description of the cell survival and biological effect at low and high dose and LET's. (springer.com)
  • OUTLINE: Tumor Cell Vaccine Therapy. (knowcancer.com)
  • This is the clinical registry of cell based therapies that is available to researchers around the world. (clinicaltrials.gov)
  • The findings, published October 11 in Cell, suggest a new avenue for developing cancer therapies by mimicking the strategies employed by the viruses. (biospace.com)
  • Stem Cell Therapy for Cancer (Brain Tumor) is quite a popular orthopedic procedure in Beijing, China. (placidway.com)
  • Focussing on the key biological endpoints of cell survival and DNA damage, this work presents a comparative investigation of the biological effectiveness of clinical proton beams using normal and radioresistant human cells. (bl.uk)
  • Cell-based therapies for amyotrophic lateral sclerosis/motor neuron disease. (degruyter.com)
  • JERUSALEM, ISRAEL--(Marketwire - Oct. 19, 2009) - Gamida Cell announced today the publication of an article evaluating carlecortemcel-l , the generic name of what is widely known as "StemEx", as a therapy for blood cancers such as leukemia and lymphoma. (marketwired.com)
  • Highly Active Anti-Retroviral Therapy (HAART) in many cases allows the stabilization of the patient's symptoms, partial recovery of CD4+ T-cell levels, and reduction in viremia (the level of virus in the blood) to low or near-undetectable levels. (wikipedia.org)
  • The role of NK cells in both the innate and adaptive immune responses is becoming increasingly important in research using NK cell activity as a potential cancer therapy. (wikipedia.org)
  • Therefore, scientists that are actively researching the role that exosomes may play in cell-to-cell signaling, often hypothesize that delivery of their cargo RNA molecules can explain biological effects. (wikipedia.org)
  • He recognized that these cells' unique ability to differentiate into all the cell types of the human body (pluripotency) had the potential to develop into a new kind of regenerative therapy. (wikipedia.org)
  • Cell therapy originated in the nineteenth century when scientists experimented by injecting animal material in an attempt to prevent and treat illness. (wikipedia.org)
  • Today two distinct categories of cell therapy are recognized. (wikipedia.org)
  • The first category is cell therapy in mainstream medicine. (wikipedia.org)
  • Cell therapy can be defined as therapy in which cellular material is injected into a patient. (wikipedia.org)
  • The origins of cell therapy can perhaps be traced to the nineteenth century, when Charles-Édouard Brown-Séquard (1817-1894) injected animal testicle extracts in an attempt to stop the effects of aging. (wikipedia.org)
  • In 1931 Paul Niehans (1882-1971) - who has been called the inventor of cell therapy - attempted to cure a patient by injecting material from calf embryos. (wikipedia.org)
  • Bone marrow transplants have been found to be effective, along with some other kinds of human cell therapy - for example in treating damaged knee cartilage. (wikipedia.org)
  • In mainstream medicine, cell therapy is supported by a distinct healthcare industry which sees strong prospects for future growth. (wikipedia.org)
  • Cell therapy is targeted at many clinical indications in multiple organs and by several modes of cell delivery. (wikipedia.org)
  • Schubert-Zsilavecz, M, Wurglics, M, Neue Arzneimittel 2009 Assessment Report for Removab Capital Market Day Fresenius Biotech: Fresenius concentrates biotechnology activities on antibody and innovative cell therapies Ruf, P. (wikipedia.org)
  • and "private storage of cord blood as 'biological insurance' is unwise" unless there is a family member with a current or potential need to undergo a stem cell transplantation. (wikipedia.org)
  • The European Medicines Agency uses the term advanced therapy medicinal products (ATMPs) for medicines for human use that are "based on genes, cells, or tissue engineering", including gene therapy medicines, somatic-cell therapy medicines, tissue-engineered medicines, and combinations thereof. (wikipedia.org)
  • Important biologics include: Whole blood and other blood components Organs and tissue transplants Stem cell therapy Antibodies for passive immunization (e.g., to treat a virus infection) Human breast milk Fecal microbiota Human reproductive cells Some biologics that were previously extracted from animals, such as insulin, are now more commonly produced by recombinant DNA. (wikipedia.org)
  • His current research interests are experimental oncology, radiobiology, biological radioprotection and cell signaling in cancer therapy. (wikipedia.org)
  • BioViva's CEO Liz Parrish appeared on Norwegian television in the program Trygdekontoret to discuss the use of gene and cell therapies to improve health in an aging population. (wikipedia.org)
  • Single-arm with switch from baseline antiretroviral therapy with Atripla to Stribild for total of 8 weeks. (clinicaltrials.gov)
  • Beaulieu DB, Ananthakrishnan AN, Martin C, Cohen RD, Kane SV, Mahadevan U. Use of Biologic Therapy by Pregnant Women With Inflammatory Bowel Disease Does Not Affect Infant Response to Vaccines. (harvard.edu)
  • Due to its broad host range and efficient replication, it has also been developed as a vector for genes encoding vaccines and anti-cancer agents, and as a tool in gene therapy. (wikipedia.org)
  • Rocco Rotello, Ph.D., associate professor of pharmaceutical sciences at Cedarville University, has entered into an agreement with Aerpio Therapeutics, a new clinical-stage biopharmaceutical company based in Cincinnati, Ohio, to work on a novel biological approach to stabilize blood vessels. (cedarville.edu)
  • However, in most cases, the term "biologics" is used more restrictively for a class of therapeutics (either approved or in development) that are produced by means of biological processes involving recombinant DNA technology. (wikipedia.org)